Alder Biopharmaceuticals (NASDAQ:ALDR) Cut to Sell at BidaskClub
Several other equities research analysts have also issued reports on the company. Svb Leerink began coverage on Alder Biopharmaceuticals in a research report on Tuesday, May 28th. They set an outperform rating on the stock. Cantor Fitzgerald reissued a buy rating and set a $25.00 price target on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. Canaccord Genuity raised Fortuna Silver Mines from a hold rating to a buy rating in a research report on Thursday, March 14th. They noted that the move was a valuation call. Leerink Swann began coverage on Alder Biopharmaceuticals in a research report on Tuesday, May 28th. They set an outperform rating and a $21.00 price target on the stock. Finally, Mizuho set a $100.00 price target on PRA Health Sciences and gave the company a hold rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $19.82.
Shares of ALDR opened at $11.45 on Tuesday. The firm has a 50 day simple moving average of $11.46. Alder Biopharmaceuticals has a 52-week low of $9.44 and a 52-week high of $20.87. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 1.21.
In related news, EVP James B. Bucher sold 1,897 shares of the company’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the completion of the transaction, the executive vice president now directly owns 11,706 shares in the company, valued at approximately $162,128.10. The sale was disclosed in a document filed with the SEC, which is available through this link. 15.40% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers grew its stake in shares of Alder Biopharmaceuticals by 77.3% in the fourth quarter. Rhumbline Advisers now owns 97,762 shares of the biopharmaceutical company’s stock worth $1,002,000 after purchasing an additional 42,624 shares in the last quarter. LPL Financial LLC grew its stake in shares of Alder Biopharmaceuticals by 43.4% in the fourth quarter. LPL Financial LLC now owns 18,175 shares of the biopharmaceutical company’s stock worth $186,000 after purchasing an additional 5,500 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Alder Biopharmaceuticals in the fourth quarter worth $176,000. Dimensional Fund Advisors LP grew its stake in shares of Alder Biopharmaceuticals by 22.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock worth $11,910,000 after purchasing an additional 215,098 shares in the last quarter. Finally, Stifel Financial Corp bought a new position in shares of Alder Biopharmaceuticals in the fourth quarter worth $154,000.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Further Reading: How do taxes affect a CDs total return?
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.